AI Article Synopsis
- Cryptosporidiosis is a common cause of diarrhea in AIDS patients, and the study aimed to assess the effectiveness of short-term azithromycin in treating it.
- The randomized trial included HIV-positive patients showing symptoms and found that while all participants experienced clinical improvement within a week, the parasite remained present in their stools.
- The conclusion highlights that azithromycin is safe and provides symptomatic relief but does not effectively eliminate the Cryptosporidium infection.
Article Abstract
Background: Cryptosporidiosis caused by the protozoa Cryptosporidium, is the common cause of diarrhoea in Acquired Immune Deficiency Syndrome (AIDS).
Aim: To study the efficacy of short-term azithromycin in the management of cryptosporidiosis.
Settings And Design: Randomised, controlled trial.
Material And Methods: All consecutive patients infected with Human Immunodeficiency Virus (HIV), who were positive for cryptosporidial oocysts were taken for this prospective randomised study.
Result: Short-term azithromycin treatment for cryptosporidial diarrhoea in AIDS patients was associated with good clinical improvement but parasitological benefit was doubtful. All 13 patients, who had symptoms of cryptosporidiosis, symptomatically improved with 5 days of treatment with azithromycin and became asymptomatic after 7 days of antibiotic, but stool sample was positive for cryptosporidium even after 7 days of therapy. After 14 days of treatment with azithromycin in 13 patients, in five patients stool was free of cryptosporidial oocyst. The drug was well tolerated in all the patients.
Conclusion: Short-term azithromycin can be used as a safe and effective treatment for symptomatic Cryptosporidiosis but not effective in eradicating Cryptosporidial infection.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Long-term forecast for antibacterial drug consumption in Germany using ARIMA models.
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Hannover Medical School, Institute of Pharmacology, D-30625, Hannover, Germany.
Article Synopsis
- This study forecasts the consumption of the top ten antibacterial drugs in Germany until 2040, using historical prescription data and ARIMA models.
- The best model for forecasting is a simple random walk with drift (ARIMA(0,1,0)), while short-term predictions show minimal variation among complex models.
- Predictions indicate rising prescriptions for some drugs like amoxicillin, but declines for others, emphasizing the need for proactive healthcare planning to address potential shortages.
[Efficacy of prolonged azithromycin versus switching to doxycycline in the treatment of macrolide-unresponsive pneumonia in children].
Zhongguo Dang Dai Er Ke Za Zhi
December 2024
Department of Pediatrics, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China.
Objectives: To investigate the efficacy and safety of prolonged azithromycin (PAZM) versus switching to doxycycline (SDXC) in the treatment of macrolide-unresponsive pneumonia (MUMPP) in children.
Methods: A total of 173 children with MUMPP who were hospitalized in Baoji Central Hospital, from January to December 2023 were selected as subjects. According to the choice of secondary antibiotic after 72 hours of initial macrolide therapy, they were divided into two groups: PAZM and SDXC.
Efficacy of Pulmicort Respules Combined with Azithromycin in the Treatment of Children with Recurrent Respiratory Tract Infection Caused by Mycoplasmal Pneumonia.
Br J Hosp Med (Lond)
November 2024
Department of Pediatrics, Huoqiu First People's Hospital, Lu'an, Anhui, China.
Article Synopsis
- * Data from 106 children were analyzed, showing that those in the observation group (pulmicort respules and azithromycin) had faster recovery times and fewer complications than those treated with azithromycin alone.
- * After one week of treatment, the observation group also showed higher inflammatory marker levels but had lower immunoglobulin levels, suggesting a more effective response to treatment, resulting in a significantly lower complication rate.
Impact of Long-Term Atorvastatin Therapy on the Development of Chronic Lung Allograft Dysfunction in Patients with Azithromycin Prophylaxis after Lung Transplantation.
Transplant Proc
November 2024
Department of Pharmacy, China-Japan Friendship Hospital, Beijing, China. Electronic address:
Objective: To assess the impact of long-term atorvastatin (ATO) therapy on reducing recipient inflammation and immune response, thus lowering the risk of chronic lung allograft dysfunction (CLAD) in lung transplant recipients. This study aimed to investigate the effects of ATO on overall survival, lung function recovery, and its influence on inflammatory factors alongside azithromycin (AZI) prophylaxis.
Methods: This retrospective single-center study included lung transplant recipients from January 2017 to December 2022.
Article Synopsis
- A multi-center randomized clinical trial compared the effectiveness of guided bone regeneration (GBR) using DBBM and NBCM against open flap debridement (OFD) for treating peri-implantitis-related bony defects over 36 months.
- The study involved 66 patients, with 34 in the GBR group receiving graft materials and 32 in the OFD control group receiving only standard decontamination treatment.
- At the end of the trial, GBR showed a trend towards better defect fill and higher treatment success rates, achieving 46.2% success compared to 20% for OFD, although these differences were not statistically significant.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!